

**STIC-ILL**

*MIC*

**From:** STIC-Biotech/ChemLib  
**Sent:** Monday, October 20, 2003 3:50 PM  
**To:** STIC-ILL  
**Subject:** FW: article request

*R II*  
*Jb 5*

-----Original Message-----

**From:** Lucas, Zacharia  
**Sent:** Monday, October 20, 2003 3:50 PM  
**T :** STIC-Biotech/ChemLib  
**Subject:** article request

**Examiner# :** 79253 Zachariah Lucas  
**Art Unit :** 1648  
**Phone Number:** 308-4240  
**Date:** 10-20-2003  
**Serial Number:** 09/827785  
**MailBox & Bldg/Room Location:** 8e12/8d16  
**Results Format Preferred (circle):** Paper

Could you please send me a copy of the following article(s).

**Biellik et al., J Infect Dis 157: 1134-41 (1988)**  
**Marchent et al., J Infect Dis 169(6): 1297-305 (1994)**  
**Mink et al., Clin Infect Dis 14(2): 464-71 (1992)**  
**Mink et al., Arch Pediatr Adolesc Med 148(2): 153-7 (1994)**  
**Keitel et al., Semin Respir Infect 10: 51-57 (1995)**

Thank you,  
Zac Lucas

**STIC-ILL**

MIC  
R II

**From:** STIC-Biotech/ChemLib  
**Sent:** Monday, October 20, 2003 3:50 PM  
**To:** STIC-ILL  
**Subject:** FW: article request

J65

-----Original Message-----

**Fr m:** Lucas, Zacharia  
**Sent:** Monday, October 20, 2003 3:50 PM  
**T :** STIC-Biotech/ChemLib  
**Subject:** article request

**Examiner# :** 79253 Zachariah Lucas  
**Art Unit :** 1648  
**Phone Number:** 308-4240  
**Date:** 10-20-2003  
**Serial Number:** 09/827785  
**MailBox & Bldg/Room Location:** 8e12/8d16  
**Results Format Preferred (circle):** Paper

Could you please send me a copy of the following article(s).

Biellik et al., J Infect Dis 157: 1134-41 (1988)  
Marchent et al., J Infect Dis 169(6): 1297-305 (1994)  
Mink et al., Clin Infect Dis 14(2): 464-71 (1992)  
Mink et al., Arch Pediatr Adolesc Med 148(2): 153-7 (1994)  
Keitel et al., Semin Respir Infect 10: 51-57 (1995)

Thank you,  
Zac Lucas

**STIC-ILL**

MIC  
R11  
R48

**From:** STIC-Biotech/ChemLib  
**Sent:** Monday, October 20, 2003 3:50 PM  
**To:** STIC-ILL  
**Subject:** FW: article request

-----Original Message-----

**From:** Lucas, Zacharia  
**Sent:** Monday, October 20, 2003 3:50 PM  
**T :** STIC-Biotech/ChemLib  
**Subject:** article request

**Examiner# :** 79253 Zachariah Lucas  
**Art Unit :** 1648  
**Phone Number:** 308-4240  
**Date:** 10-20-2003  
**Serial Number:** 09/827785  
**MailBox & Bldg/Room Location:** 8e12/8d16  
**Results Format Preferred (circle):** Paper

Could you please send me a copy of the following article(s).

Biellik et al., J Infect Dis 157: 1134-41 (1988)  
Marchent et al., J Infect Dis 169(6): 1297-305 (1994)  
Mink et al., Clin Infect Dis 14(2): 464-71 (1992)  
Mink et al., Arch Pediatr Adolesc Med 148(2): 153-7 (1994)  
Keitel et al., Semin Respir Infect 10: 51-57 (1995)

Thank you,  
Zac Lucas



National  
Library  
of Medicine

Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Etc

Search **PubMed** for **pertussis AND adult AND diphtheria**

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

[Help | FAQ](#)

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

### Search

### Most Recent Queries

Time Result

#4 Search **pertussis AND adult AND diphtheria** Field: **Title/Abstract, Limits: Publication Date to 1996/11/07** 16:17:18 17

#2 Search **pertussis AND adult AND DPT** Field: **Title/Abstract, Limits: Publication Date to 1996/11/07** 16:16:32 1

#1 Search **pertussis AND adult** Field: **Title/Abstract, Limits: Publication Date to 1996/11/07** 16:16:18 230

### Related Resources

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[Privacy Policy](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Oct 14 2003 07:20:40



National  
Library  
of Medicine



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Ec

Search PubMed

for

Go

Clear

 Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show: 20

Sort

Send to

Text

Text Version

□ 1: Tokai J Exp Clin Med. 1988;13 Suppl:125-8.

Related Articles, Link

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

## Pertussis in adults: possible use of booster doses for control.

**Hewlett EL.**

Department of Internal Medicine, University of Virginia School of Medicine Charlottesville 22908.

Adolescents and adults represent an increasing proportion of the relatively fixed number of reported pertussis cases in the United States each year. Widespread use of pertussis vaccine in the pediatric population has resulted in more individuals reaching adulthood without having had the disease. Since pertussis vaccine is not recommended for routine use in persons over 6 years of age, the loss of vaccine immunity with time after immunization provides a continuous supply of susceptibles (beginning during the teen years) in the population. It has been suggested that whole cell pertussis vaccine is more reactogenic in adults than in children. The data, however, indicate that the rates of local and systemic reactions are equivalent to those reported for children receiving routine pertussis immunization. Nevertheless, because pertussis is not a life-threatening illness in adults, the allegations against and perceptions about the vaccine cannot be overcome and whole cell PDT will never be used routinely in adults. The development of acellular pertussis vaccines, however, provides a novel opportunity for consideration of immunization of the adult population. In phase I trials, acellular pertussis vaccine has been given to adults with minimal reactions and good immunogenicity. Preparations containing pertussis toxin (PT) and filamentous hemagglutinin (FHA) were associated with greater frequency of local reactions to doses following the first. These data indicate that routine booster immunization of the adult population, probably every 10 years with tetanus-diphtheria toxoids (Td), is feasible and might be beneficial in control of pertussis. A major hurdle in consideration of such a policy will be theoretical acceptance by the medical community and lay public.

### Publication Types:

- Review
- Review, Tutorial

PMID: 3078801 [PubMed - indexed for MEDLINE]



National  
Library  
of Medicine

Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Etc

Search PubMed

for

Limits

Preview/Index

History

Clipboard

Details

About Entrez



Text Version

Show:

Related Articles, Link

**[V] 1: J Infect Dis. 1995 Apr;171(4):1053-6.**

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

Privacy Policy

## Use and safety of acellular pertussis vaccine among adult hospital staff during an outbreak of pertussis.

**Shefer A, Dales L, Nelson M, Werner B, Baron R, Jackson R.**

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia 30333.

During May and June 1993, 10 patients and 5 members of the clinical staff at a hospital in California were diagnosed with *Bordetella pertussis* infection. In addition to erythromycin prophylaxis, 630 (48%) of 1330 staff members received a half dose of acellular pertussis vaccine with tetanus and diphtheria toxoids (DTaP). To identify side effects of the vaccine, a questionnaire was completed by 344 (54%) of 630 vaccinated staff. Side effects were reported by 117 respondents (34%); 64 were classified as mild (local reaction at injection site) and 50 as moderate (systemic complaints or local reaction resulting in limitation of arm movement). Three vaccinees (<1%) reported missing 1 or more days of work because of their symptoms. Local reactions at the injection site occurred in 100 (29%), systemic symptoms in 38 (11%), and limitation of arm movement in 18 (5%). This study indicates that use of half dose of DTaP in adults appears safe and should be considered as an adjunct to chemoprophylaxis during institutional outbreaks.

### Publication Types:

- Clinical Trial

PMID: 7706789 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Oct 14 2005 07:26



National  
Library  
of Medicine

Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Eo

Search **PubMed**

for

**Go**

**Clear**

Limits

Preview/Index

History

Clipboard

Details

About Entrez

**Display** **Abstract**

Show:

**20**

**Sort**

**Send to** **Text**

Text Version

1: *JAMA*. 1993 Jan 6;269(1):53-6.

Related Articles, Link

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

Comment in:

- *JAMA*. 1993 Jan 6;269(1):93-4.

## Adult immunization with acellular pertussis vaccine.

**Edwards KM, Decker MD, Graham BS, Mezzatesta J, Scott J, Hackell J**

Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tenn.

**OBJECTIVE**--To evaluate the safety and immunogenicity in adults of several different concentrations of an acellular pertussis vaccine. **DESIGN**--Double-blind, randomized, placebo-controlled trial. **SETTING**--Medical center immunization clinic. **PARTICIPANTS**--One hundred eighteen healthy adult volunteers. **INTERVENTIONS**--Participants received standard adult tetanus-diphtheria vaccine alone or combined with full-strength, half-strength, or quarter-strength concentrations of a currently licensed acellular pertussis vaccine used for booster doses in young children. Full-strength vaccine contained 40 micrograms of pertussis proteins, consisting of 86% filamentous hemagglutinin, 8% pertussis toxin, 4% 69-kd outer-membrane protein, and 2% agglutinogens. **MAIN OUTCOME MEASURES**--Local and systemic reactions were assessed for 14 days after vaccination. Serum samples for antibody assay were obtained before, 1 month after, and 1 year after immunization. **RESULTS**--Adverse reactions were few and minor and did not differ in frequency or severity among the four study groups. The groups receiving acellular pertussis vaccine showed strong antibody responses to pertussis antigens, which did not significantly differ by concentration of vaccine. After 1 year, levels of antibody to pertussis had declined by approximately 50% but remained substantially higher than preimmunization levels. The four groups did not differ in antibody responses to tetanus or diphtheria toxoids. **CONCLUSIONS**--Routine reimmunization of adults with a vaccine containing acellular pertussis antigens in addition to diphtheria and tetanus toxoids can substantially enhance pertussis antibody levels without an increase in adverse reactions or diminution in response to the diphtheria and tetanus components. Such a program might materially reduce respiratory illness among both adults and children.

Publication Types: